Core Insights - The approval of VELSIPITY® (Argenine Acquimod Tablets) by the NMPA marks a significant advancement for the company in the treatment of moderate to severe active ulcerative colitis (UC) in adults, filling a critical gap in the market [1][2] - The drug is expected to reach peak sales of 5 billion RMB, becoming a core product alongside the existing drug in the nephrology field, indicating a new phase of rapid growth for the company [1][6] Group 1: Product Approval and Market Potential - VELSIPITY® is a next-generation high-selectivity S1P receptor modulator that offers rapid onset and effective deep mucosal healing, providing a new first-line treatment option for UC patients [1][3] - The incidence of UC in China is rising, with projections indicating an increase from approximately 980,000 patients in 2025 to about 1.5 million by 2031, highlighting the growing need for effective treatments [2] - Current treatment options are limited, with only 24% of UC patients achieving mucosal healing, underscoring the unmet clinical needs that VELSIPITY® aims to address [2][3] Group 2: Clinical Efficacy and Recognition - Clinical trials have shown that VELSIPITY® has a clinical remission rate of 48.1% and a mucosal healing rate of 51.9% after 40 weeks of maintenance treatment, demonstrating its significant clinical advantages [3][4] - The drug has been included in major international clinical guidelines, such as the 2024 AGA guidelines and the 2025 ACG guidelines, receiving strong recommendations for its use in moderate to severe UC [4] Group 3: Commercialization Strategy and Growth - The company has developed a comprehensive A2MS (Access, Medical, Market, Sales) operational system to efficiently promote VELSIPITY®'s market entry and maximize its therapeutic value [5][6] - The approval of VELSIPITY® signifies a major breakthrough in the autoimmune disease sector, enhancing the company's product matrix and expected to significantly boost revenue and profitability [6][7] - The company aims to achieve over 10 billion RMB in revenue by 2028 and over 15 billion RMB by 2030, with a projected annual growth rate exceeding 50% from 2025 to 2030 [7]

Core Viewpoint - The approval of VELSIPITY® for the treatment of moderate to severe active ulcerative colitis (UC) in adults marks a significant milestone for the company and aligns with its 2030 development strategy [1] Company Developments - The National Medical Products Administration (NMPA) of China has approved the new drug application for VELSIPITY® (Arginine Acquimod Tablets) [1] - The company plans to actively prepare for the commercialization of VELSIPITY® and aims to expedite its availability to domestic patients while promoting its inclusion in the national medical insurance catalog [1] Strategic Goals - The approval of VELSIPITY® is part of the company's broader 2030 development strategy, which emphasizes a dual approach of "BD collaboration + self-research" to create both certain commercial value and growth-oriented research and development value [1] - The company intends to continue strengthening its core therapeutic area advantages, advancing innovative drug research and commercialization, and establishing itself as a sustainable growth global innovative biopharmaceutical enterprise [1]

Core Insights - The approval of VELSIPITY® (Argenine Acquimod Tablets) by the NMPA marks a significant milestone for the company in the autoimmune field, providing a new first-line treatment option for adult patients with moderate to severe active ulcerative colitis (UC) who have inadequate response to traditional therapies or biologics [1][2] - The company aims to commercialize VELSIPITY® quickly and is actively working to include it in the national medical insurance directory, aligning with its 2030 development strategy focused on dual-driven growth through BD collaboration and self-research [2][4] Group 1: Product and Clinical Research - VELSIPITY® is a next-generation high-selectivity sphingosine-1-phosphate (S1P) receptor modulator, administered once daily, demonstrating rapid onset and strong mucosal healing with good safety characteristics [1] - The approval is based on results from the largest Asian Phase III registration clinical study (ENLIGHTUC) involving 340 patients, as well as global Phase III studies (ELEVATEUC52 and ELEVATEUC12) that confirmed the drug's favorable benefit-risk profile [1][2] Group 2: Commercialization Strategy - The company has established a commercialization platform with three products and is focused on building a comprehensive commercialization system and drug lifecycle management capabilities [3] - Revenue targets include exceeding 10 billion RMB by 2028 and over 15 billion RMB by 2030, with an expected compound annual growth rate of over 50% from 2025 to 2030 [3] Group 3: Future Growth and Strategic Goals - The 2030 development strategy emphasizes a dual-driven approach of BD collaboration and self-research, aiming to introduce 3 to 5 late-stage blockbuster products annually and achieve peak sales within three years post-reimbursement [4] - The company plans to introduce over 20 high-value assets by 2030, contributing approximately 6 billion RMB in revenue, with a long-term goal of reaching around 30 billion RMB by 2035 [4]

Core Viewpoint - The approval of VELSIPITY® (Arginine Acquimod Tablets) by the NMPA marks a significant milestone for the company in establishing its leading position in the autoimmune field, providing a new first-line treatment option for adult patients with moderate to severe active ulcerative colitis who have inadequate response to traditional therapies or biologics [1][3] Group 1: Product Approval and Clinical Research - VELSIPITY® is a next-generation high-selectivity sphingosine-1-phosphate (S1P) receptor modulator, administered once daily, demonstrating rapid onset and strong mucosal healing efficacy with good safety characteristics [2] - The approval is based on results from the ENLIGHT UC study, the largest Phase III registration clinical trial for moderate to severe active ulcerative colitis patients in Asia, involving 340 patients, achieving statistical significance and clinical relevance in all primary and secondary efficacy endpoints [2] - The ELEVATE UC Phase III studies further validated the benefit-risk profile of VELSIPITY®, with ELEVATE UC 52 and ELEVATE UC 12 being randomized, double-blind, placebo-controlled trials [2] Group 2: Commercialization Strategy - The company is preparing for the commercialization of VELSIPITY® and aims to expedite its availability to domestic patients while actively promoting its inclusion in the national medical insurance catalog [3] - The approval aligns with the company's 2030 development strategy, which emphasizes a dual approach of "BD collaboration + self-research" to create certain value through commercialization and growth through research and development [3][5] - The company plans to establish a comprehensive commercialization system and aims to achieve revenue exceeding 10 billion RMB by 2028 and over 15 billion RMB by 2030, with a projected compound annual growth rate of over 50% from 2025 to 2030 [4] Group 3: Future Growth and Globalization - The 2030 development strategy signifies a critical milestone for the company in advancing to the forefront of global biopharmaceuticals, focusing on a product portfolio that captures blue ocean opportunities [5] - The company intends to introduce 3 to 5 late-stage blockbuster products annually and aims to contribute 6 billion RMB in revenue from over 20 high-value assets by 2030, with a long-term goal of approximately 30 billion RMB by 2035 [5] - The company is also initiating a globalization strategy to enhance its global registration and clinical development capabilities, aiming for accelerated international growth through a dual engine of "overseas licensing + commercialization" [4]